Showing 1061-1070 of 19239 results for "".
Investigating the Circulation of Counterfeit COVID-19 Medications
https://reachmd.com/programs/covid-19-frontlines/investigating-the-circulation-of-counterfeit-covid-19-medications/11624/The worldwide shortfall of drugs and drug supplies has fueled an illicit trade market for illegal pharmaceuticals and medical items.Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19
https://reachmd.com/programs/the-drug-report/renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-covid-19/11416/Do the benefits of continuing the use of RAAS inhibitors in patients outweigh the risks due to the inhibitors’ potential link to COVID-19 severity?Understanding Dual Inhibition of IL-17
https://reachmd.com/programs/medical-industry-feature/understanding-dual-inhibition-of-il-17/32263/IL-17A and IL-17F play significant roles in rheumatic and psoriatic diseases as they trigger downstream pro-inflammatory responses.1,2 Targeting both IL-17A + IL-17F in vitro provides more inhibition of inflammation vs targeting IL-17A alone.*3-5 BIMZELX (bimekizumab-bkzx) is the only approved theraIntegrating Guideline Updates in Squamous Cell Carcinoma of the Anal Canal
https://reachmd.com/programs/project-oncology/guideline-updates-anal-canal-squamous-cell-carcinoma/54280/As NCCN® Clinical Practice Guidelines in Oncology evolve, integrating chemoimmunotherapy into the management of advanced squamous cell carcinoma of the anal canal requires thoughtful, patient-centered decision-making. That’s why Dr. Stacey Cohen joins Dr. Charles Turck to translate updated recommendRevolutionizing Aesthetic Medicine and Dermatology with Artificial Intelligence
https://modernaesthetics.com/ma-issues-index/2025-mar-apr/revolutionizing-aesthetic-medicine-and-dermatology-with-artificial-intelligence/36064/This article explores the possibilities of AI and how it can be ethically utilized to enhance aesthetic medicine and marketing to grow one’s practice to its maximum potential.Diagnosing IBD: Is It IBD or Something Else? Can You Tell?
https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.IBD Immunopathogenesis: Do You Know What You're Blocking?
https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
https://reachmd.com/programs/cme/transformative-insights-latest-evidence-for-b7-h3-adcs-from-wclc-and-esmo-2025/36238/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
https://reachmd.com/programs/cme/ttr-levels-and-associated-disease-risk-insights-from-2025-pns-conference/36192/Review recent data from the UK Biobank showing the increased risk of vascular and cognitive comorbidities associated with naturally low transthyretin levels.Incorporating Targeted Therapies in Treatment Planning for AAV
https://reachmd.com/programs/cme/incorporating-targeted-therapies-in-treatment-planning-for-aav/14962/Our experts offer tips to effectively manage your patients with AAV & improve their quality of life by incorporating C5a receptor antagonist therapy.